Stay Ahead of Wall Street. Find out what is happening to Atara Biotherapeutics, Inc. (NASDAQ:ATRA) stock today? Its price is jumping 0.7 points, trading at $15.44 levels, and is up 4.75% from its previous close of $14.74. The shares seem to have an active trading volume day with a reported 480361 contracts so far this session. ATRA shares had a relatively better volume day versus average trading capacity of 811.93 thousand shares, but with a 51.53 million float and a 9.19% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ATRA stock indicates that the average analyst price target is $36.86 per share. This means the stock has a potential increase of 138.73% from where the ATRA share price has been trading recently which is between $13.4705 and $14.78.
The shorts are climbing into Atara Biotherapeutics, Inc. (ATRA) stock. The latest set of short interest data was released on 15 August 2019, and the numbers show a rise in short interest in ATRA shares. While short interest still represents only 16.63% of ATRA’s float, the number of shares shorted have risen by 454425. The number of shares shorted advanced to 8570499 shares, up from 8116074 shares during the preceding fortnight. With average daily trading volumes at 935965 shares, days to cover increased to about 7.806364 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Baupost’s Seth Klarman Dives Further Into Translate Bio” and dated September 10, 2019.
During the recent trading session for Atara Biotherapeutics, Inc. (NASDAQ:ATRA), the company witnessed their stock rise $2.83 over a week and surge $1.96 from the price 20 days ago. When compared to their established 52-week high of $43.95, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 09/26/18. The recent low of $11.89 stood for a -64.87% since 08/08/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.09 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Atara Biotherapeutics, Inc., the two-week RSI stands at 59.41. This figure suggests that ATRA stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current ATRA readings is similarly very revealing as it has a stochastic reading of 93.43% at this stage. This figure means that ATRA share price today is being oversold.
Technical chart claims that Atara Biotherapeutics, Inc. (ATRA) would settle between $15.19/share to $15.64/share level. However, if the stock price goes below the $13.88 mark, then the market for Atara Biotherapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $13.02 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.92. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Citigroup raised their recommendation on shares of ATRA from Sell to Neutral in their opinion released on June 04. ROTH Capital, analysts launched coverage of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) stock with a Buy recommendation, according to their flash note issued to investors on May 30. Analysts at Stifel, made their first call for the equity with a Buy recommendation, according to a research note that dated back to May 23.
ATRA equity has an average rating of 1.25, with the figure leaning towards a bullish end. 8 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 7 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 7 analysts rated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, ATRA stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/E ratio is NA while for the average stock in the same group, the multiple is -6.49. Atara Biotherapeutics, Inc. current P/B ratio of 2.94 means it is trading at a discount against its industry’s 3.44.